Literature DB >> 3116663

Idiotype-anti-idiotype interactions of VHIX-coded anti-progesterone and anti-arsonate antibodies. Comparison of passive haemagglutination and radioimmunoassays.

M J Taussig1, D Kirk, M W Wang, S Ellis, K Meek, J Marvel, J Urbain, R R Coombs.   

Abstract

The reactivity and specificity of polyclonal and monoclonal anti-idiotypic antibodies raised against monoclonal anti-progesterone and anti-arsonate antibodies have been studied by solid phase radioimmunoassay (RIA) with immobilized idiotype and by passive haemagglutination with idiotype-coupled red cells. The sensitivity of the two methods was comparable, though some cross-reactions were only detected by RIA. Passive haemagglutination was found to be especially suitable in screening for monoclonal anti-idiotypes in hybridoma supernatants and ascites, and had advantages over RIA in detection of syngeneic anti-idiotypes. Demonstration of binding site-associated idiotopes was possible by haemagglutination inhibition. RIA and haemagglutination were used to investigate the idiotypic relationships between BALB/c antiprogesterone and anti-arsonate monoclonal antibodies which share heavy chains encoded by VHIX variable region genes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116663     DOI: 10.1111/j.1365-3083.1987.tb02260.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Blocking of pregnancy in mice by immunization with anti-idiotype directed against monoclonal anti-progesterone antibody.

Authors:  M W Wang; R B Heap; M J Taussig
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

2.  Induction of anti-progesterone immunity and pregnancy blocking by anti-progesterone anti-idiotypes. Variable efficacy of polyclonal Ab2 antibodies directed against a panel of closely related Ab1 antibodies.

Authors:  M W Wang; M J Sims; P R Symington; A S Humphreys; M J Taussig
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.